Biotinylated Mouse IL-15 Protein, Fc,Avitag™

Source : 

Biotinylated Mouse IL-15, Fc,Avitag (IL5-M82F3) is expressed from human 293 cells (HEK293). It contains AA Asn 49 - Ser 162 (Accession # P48346-1).

 

Molecule : IL-15

 

Synonyms : IL-15,Interleukin-15,MGC9721

 

Format : Powder

 

Category : MABSol® Biotin Labeled Proteins

 

Accession :  NP_032383.1

 

Storage : -20℃

 

Shipping condition : Powder,RT

 

Molecular Weight : 41.5 kDa

 

Characteristics :

This protein carries a human IgG1 Fc tag at the C-terminus, followed by a Avi tag (Avitag™). The protein has a calculated MW of 41.5 kDa. The protein migrates as 50-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

 

Endotoxin Level : Less than 1.0 EU per μg by the LAL method.

 

Buffer : Tris with Glycine, Arginine and NaCl, pH7.5

 

Description :

Interleukin 15 is also known as IL15, IL-15, and is a cytokine with structural similarity to IL-2. Like IL-2, IL-15 binds to and signals through the IL-2/IL-15 beta chain (CD122) and the common gamma chain (gamma-C, CD132). IL-15 is secreted by mononuclear phagocytes (and some other cells) following infection by virus(es). This cytokine induces cell proliferation of natural killer cells; cells of the innate immune system whose principal role is to kill virally infected cells. Interleukin 15 (IL-15) regulates T and natural killer (NK) cell activation and proliferation. Survival signals that maintain memory T cells in the absence of antigen are provided by IL-15. This cytokine is also implicated in NK cell development. In rodent lymphocytes, IL-15 prevents apoptosis by inducing an apoptosis inhibitor, BCL2L1/BCL-x(L). IL-15 has been shown to enhance the anti-tumor immunity of CD8+ T cells in pre-clinical models. A phase I clinical trial to evaluate the safety, dosing, and anti-tumor efficacy of IL-15 in patients with metastatic melanoma and renal cell carcinoma (kidney cancer) has begun to enroll patients at the National Institutes of Health.

 

References :

(1) Grabstein KH, et al. 1994, Science 264 (5161): 965–8.
(2) Malamut G, et al. 2010, J. Clin. Invest. 120 (6): 2131–43.
(3) Klebanoff CA, et al. 2004, Proc. Natl. Acad. Sci. U.S.A. 101 (7): 1969–74.
(4) Teague RM, et al. 2006, Nat. Med. 12 (3): 335–41.